INF179KC1HO1
The HDFC Pharma and Healthcare Fund aims to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
The fund operates as an open-ended equity scheme investing in Pharma and healthcare companies. The investment strategy focuses on identifying opportunities within India's pharmaceutical and healthcare sectors, which include pharmaceutical manufacturers, biotechnology companies, healthcare service providers, and medical device companies.
Key investment features include:
- Sector Focus: Concentrated exposure to pharmaceutical and healthcare industries
- Investment Universe: Primarily equity and equity-related instruments of pharma and healthcare companies
- Long-term Approach: Designed for capital appreciation over extended investment horizons
- Risk Profile: The fund is rated Very High risk due to its sectoral nature
The scheme being sectoral in nature carries higher risks versus diversified equity mutual funds on account of concentration and sector specific risks.
The HDFC Pharma and Healthcare Fund is managed by a team of experienced professionals:
Mr. Nikhil Mathur - Nikhil Mathur is the Current Fund Manager of HDFC Pharma And Healthcare Fund Direct Growth fund. Mr. Mathur has done B.Tech and PGDM in Finance. Prior to joining HDFC Mutual Fund, he has worked with Ambit Capital, Goldman Sachs, Deloitte India and EY.
Mr. Dhruv Muchhal - Mr. Dhruv Muchhal serves as Equity Analyst and Fund Manager for Overseas Investments. Mr. Dhruv has done B.Com, CA and CFA. Prior to joining HDFC MF, he has worked with Motilal Oswal Financial Services Ltd., Goldman Sachs, CRISIL Global Research & Analytics and Deloitte Haskins & Sells.
The fund management team brings extensive experience in equity research, financial analysis, and portfolio management, with strong backgrounds in both domestic and international markets.
HDFC Mutual Fund, established as one of India's leading asset management companies, manages the HDFC Pharma and Healthcare Fund. The AMC has built a reputation for delivering consistent performance across various fund categories and maintaining robust investment processes.
HDFC Mutual Fund operates with a philosophy of disciplined investing and thorough research-driven stock selection. The fund house has established strong track records across equity, debt, and hybrid fund categories, making it a trusted choice among Indian investors.
Key highlights of HDFC Mutual Fund:
- Strong research capabilities with experienced fund management teams
- Comprehensive range of mutual fund products across categories
- Focus on long-term wealth creation through disciplined investment processes
- Robust risk management frameworks and compliance standards
The HDFC Pharma and Healthcare Fund may be suitable for specific investor profiles, but requires careful consideration due to its sectoral nature.
Who Should Consider This Fund:
- Investors with strong conviction about India's pharmaceutical and healthcare sector growth potential
- Those seeking concentrated exposure to pharma and healthcare companies
- Investors with high risk tolerance and long-term investment horizon (minimum 7+ years)
- Portfolio diversification seekers who already have diversified equity exposure
Investment Considerations:
Investment experts believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
However, if you do invest, you must do so only through the SIP route. Investors are advised not to invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.
Risk Factors:
- High volatility due to sector concentration
- Regulatory changes affecting pharmaceutical industry
- Patent expirations and drug approval uncertainties
- Currency fluctuation impact on export-dependent pharma companies
Investment Requirements:
- Minimum SIP Investment is set to ₹100
- Minimum Lumpsum Investment is ₹100
- Exit load of 1%, if redeemed within 30 days
The NAV changes daily based on market movements. You can check the current NAV on the HDFC Mutual Fund website or financial portals like Groww, Angel One, or Zerodha Coin for real-time updates.
The fund currently has an Asset Under Management (AUM) of ₹8,65,702 Cr as of 22 Aug 2025. The AUM reflects the total value of assets managed by the fund.
The expense ratio varies between regular and direct plans. Direct plans typically have lower expense ratios. Check the latest scheme documents or fund factsheets for current expense ratio details.
The scheme return performance since scheme launch is 78.01%. However, past performance doesn't guarantee future returns, and sectoral funds can be highly volatile.
The minimum SIP amount to invest in this scheme is ₹100. This makes it accessible for investors starting with small amounts.
You can invest through Allvest's platform by completing KYC requirements, selecting the fund, choosing investment amount and mode (SIP/lump sum), and completing the investment process online.
On Allvest platform, select the fund, choose SIP option, set your monthly investment amount (minimum ₹100), select investment date, and set up auto-debit from your bank account.
Enable auto-debit facility through Allvest platform by linking your bank account, setting up NACH/e-NACH mandate, which will automatically deduct the SIP amount on your chosen date each month.
You can redeem through Allvest platform by logging into your account, selecting the fund, choosing redemption amount (partial/full), and submitting the request. Note that exit load of 1% applies if redeemed within 30 days.
Clients/Investors to abstain them from dealing in any schemes of unauthorised collective investments / portfolio management, indicative/ guaranteed/fixed returns / payments etc.
Sr. No
Name of KMP
Designation
Mobile Number
Email ID
2.
Mr. Amit Bansal
Designated Director /
Compliance Officer